Claims for Patent: 4,933,324

Summary for Patent: 4,933,324

Title:	Fatty acid-neuroactive drug conjugate as a prodrug
Abstract:	The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be digested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.
Inventor(s):	Shashoua; Victor E. (Brookline, MA)
Assignee:
Application Number:	07/315,134
Patent Claims:	1. A prodrug compound capable of facilitating the passage of drug across the blood-brain barrier comprising: ##STR8## wherein D is a nueroactive drug selected from the group consisting of dopamine, serotonin, .gamma.-aminobutyric acid, norepinephrine, apomorphine, histamine, epinephrine, glycine, aspartic acid, glutamic acid, taurine, phefluoramine, amphetamine, met-enkephalin, and diethylpropion. 2. A prodrug as claimed in claim 1 wherein said drug is dopamine. 3. A prodrug as claimed in claim 1 wherein said drug is serotonin. 4. A prodrug as claimed in claim 1 wherein said drug is .gamma.-aminobutyric acid. 5. A prodrug as claimed in claim 1 wherein said drug is apomorphine. 6. A prodrug as claimed in claim 1 wherein said drug is norepinephrine. 7. A prodrug compound as claimed in claim 1 wherein the drug is histamine. 8. A prodrug compound as claimed in claim 1 wherein the drug is epinephrine. 9. A prodrug compound as claimed in claim 1 wherein the drug is glycine. 10. A prodrug compound as claimed in claim 1 wherein the drug is aspartic acid. 11. A prodrug as claimed in claim 1 wherein the drug is glutamic acid. 12. A prodrug as claimed in claim 1 wherein the drug is taurine. 13. A prodrug as claimed in claim 1 wherein the drug is phefluoramine. 14. A prodrug as claimed in claim 1 wherein the drug is amphetamine. 15. A prodrug as claimed in claim 1 wherein the drug is met-enkephalin. 16. A prodrug as claimed in claim 1 wherein the drug is diethylpropion. 17. A prodrug as claimed in any one of claims 2-16 in which the bond between the fatty acid carrier and the drug is an amide bond. 18. A prodrug as claimed in any one of claims 2-16 in which the bond between the fatty acid carrier and the drug is an ester bond. 19. A prodrug as claimed in any one of claims 2-16 further comprising a pharmaceutically acceptable carrier. 20. A prodrug compound as claimed in claim 19 wherein the prodrug is formulated into capsule form suitable for oral administration. 21. A prodrug as claimed in claim 19 wherein the prodrug is coated to permit the bond between the fatty acid and the drug to survive the conditions in the stomach. 22. A prodrug as claimed in any one of claims 2-16 wherein at least one of the hydrogens of the fatty acid carrier is replaced with a methyl, ethyl, or isopropyl substituent. 23. A prodrug as claimed in claim 22 having a BPI index of at least two times the BPI index of the drug molecule. 24. A prodrug compound capable of facilitating the passage of a drug across the blood-brain barrier comprising: ##STR9## wherein D is a neuroactive drug selected from the group consisting of dopamine, serotonin, .gamma.-aminobutyric acid, norepinephrine, apomorphine, histamine, epinephrine, glycine, aspartic acid, glutamic acid, taurine, phefluoramine, amphetamine, met-enkephalin, and diethylpropion. 25. A prodrug as claimed in claim 24 wherein said drug is dopamine. 26. A prodrug as claimed in claim 24 wherein said drug is serotonin. 27. A prodrug as claimed in claim 24 wherein said drug is .gamma.-aminobutyric acid. 28. A prodrug as claimed in claim 24 wherein said drug is apomorphine. 29. A prodrug is claimed in claim 24 wherein said drug is norepinephrine. 30. A prodrug as claimed in claim 24 wherein the drug is histamine. 31. A prodrug as claimed in claim 24 wherein the drug is epinephrine. 32. A prodrug as claimed in claim 24 wherein the drug is glycine. 33. A prodrug as claimed in claim 24 wherein the drug is aspartic acid. 34. A prodrug as claimed in claim 24 wherein the drug is glutamic acid. 35. A prodrug as claimed in claim 24 wherein the drug is taurine. 36. A prodrug as claimed in claim 24 wherein the drug is phefluoramine. 37. A prodrug as claimed in claim 24 wherein the drug is amphetamine. 38. A prodrug as claimed in claim 24 wherein the drug is met-enkephalin. 39. A prodrug as claimed in claim 24 wherein the drug is diethylpropion. 40. A prodrug as claimed in claim 24 having a BPI index of at least two times BPI index of the drug molecule. 41. A prodrug as claimed in any one of claims 25-39 in which the bond between the fatty acid carrier and the drug is an amide bond. 42. A prodrug as claimed in any one of claims 25-39 in which the bond between the fatty acid carrier and the drug is an ester bond. 43. A prodrug as claimed in any one of claim 25-39 further comprising a pharmaceutically acceptable carrier. 44. A prodrug compound as claimed in claim 43 wherein the prodrug is formulated into capsule form suitable for oral administration. 45. A prodrug compound as claimed in claim 44 wherein the capsule is a slow release capsule. 46. A prodrug compound as claimed in claim 43 wherein the prodrug is formulated into tablet form suitable for oral administration. 47. A prodrug as claimed in claim 43 wherein the prodrug is coated to permit the bond between the fatty acid and the drug to survive the conditions in the stomach. 48. A prodrug as claimed in nay one of claims 25-39 wherein at least one of the hydrogens of the fatty acid carrier is replaced with a methyl, ethyl, or isopropyl substituent.

Details for Patent 4,933,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2008-02-26